Conversion of water-soluble CBD to ∆9-THC in synthetic gastric fluid—An unlikely cause of positive drug tests

Abstract Cannabidiol (CBD) has been shown to convert to ∆9-tetrahydrocannabinol (∆9-THC) in acidic environments, raising a concern of conversion when exposed to gastric fluid after consumption. Using synthetic gastric fluid (SGF), it has been demonstrated that the conversion requires surfactants, su...

Full description

Saved in:
Bibliographic Details
Published inJournal of analytical toxicology Vol. 47; no. 7; pp. 632 - 635
Main Authors Hart, E. Dale, Mullen, Lawrance, Vikingsson, Svante, Cone, Edward J, Winecker, Ruth E, Hayes, Eugene D, Flegel, Ronald R
Format Journal Article
LanguageEnglish
Published 15.09.2023
Online AccessGet full text

Cover

Loading…
Abstract Abstract Cannabidiol (CBD) has been shown to convert to ∆9-tetrahydrocannabinol (∆9-THC) in acidic environments, raising a concern of conversion when exposed to gastric fluid after consumption. Using synthetic gastric fluid (SGF), it has been demonstrated that the conversion requires surfactants, such as sodium dodecyl sulfate (SDS), due to limited solubility of CBD. Recently, water-compatible nanoemulsions of CBD have been prepared as a means of fortifying beverages and water-based foods with CBD. Since these emulsions contain surfactants as part of their formulation, it is possible that these preparations might enhance the production of ∆9-THC even in the absence of added surfactants. Three THC-free CBD products, an oil, an anhydrous powder and a water-soluble formulation, were incubated for 3 h in SGF without SDS. The water-soluble CBD product produced a dispersion, while the powder and the oil did not mix with the SGF. No THC was detected with the CBD oil (<0.0006% conversion), and up to 0.063% and 0.0045% conversion to ∆9-THC was observed with the water-soluble CBD and the CBD powder, respectively. No formation of ∆8-THC was observed. In comparison, when the nano-formulated CBD was incubated in SGF with 1% SDS, 33–36% conversion to ∆9-THC was observed. Even though the rate of conversion with the water-soluble CBD was at least 100-fold higher compared to the CBD oil, it was still smaller than ∆9-THC levels reported in CBD products labeled “THC-free” or “<0.3% THC” based on the Agricultural Improvement Act of 2018 (the Farm Bill). Assuming a daily CBD dose of around 30 mg/day, it is unlikely that conversion of CBD to ∆9-THC could produce a positive urinary drug test for 11-Nor-9-carboxy-∆9-THC (15 ng/mL cut-off).
AbstractList Abstract Cannabidiol (CBD) has been shown to convert to ∆9-tetrahydrocannabinol (∆9-THC) in acidic environments, raising a concern of conversion when exposed to gastric fluid after consumption. Using synthetic gastric fluid (SGF), it has been demonstrated that the conversion requires surfactants, such as sodium dodecyl sulfate (SDS), due to limited solubility of CBD. Recently, water-compatible nanoemulsions of CBD have been prepared as a means of fortifying beverages and water-based foods with CBD. Since these emulsions contain surfactants as part of their formulation, it is possible that these preparations might enhance the production of ∆9-THC even in the absence of added surfactants. Three THC-free CBD products, an oil, an anhydrous powder and a water-soluble formulation, were incubated for 3 h in SGF without SDS. The water-soluble CBD product produced a dispersion, while the powder and the oil did not mix with the SGF. No THC was detected with the CBD oil (<0.0006% conversion), and up to 0.063% and 0.0045% conversion to ∆9-THC was observed with the water-soluble CBD and the CBD powder, respectively. No formation of ∆8-THC was observed. In comparison, when the nano-formulated CBD was incubated in SGF with 1% SDS, 33–36% conversion to ∆9-THC was observed. Even though the rate of conversion with the water-soluble CBD was at least 100-fold higher compared to the CBD oil, it was still smaller than ∆9-THC levels reported in CBD products labeled “THC-free” or “<0.3% THC” based on the Agricultural Improvement Act of 2018 (the Farm Bill). Assuming a daily CBD dose of around 30 mg/day, it is unlikely that conversion of CBD to ∆9-THC could produce a positive urinary drug test for 11-Nor-9-carboxy-∆9-THC (15 ng/mL cut-off).
Author Flegel, Ronald R
Vikingsson, Svante
Winecker, Ruth E
Mullen, Lawrance
Hayes, Eugene D
Cone, Edward J
Hart, E. Dale
Author_xml – sequence: 1
  givenname: E. Dale
  surname: Hart
  fullname: Hart, E. Dale
– sequence: 2
  givenname: Lawrance
  orcidid: 0000-0001-9397-8582
  surname: Mullen
  fullname: Mullen, Lawrance
– sequence: 3
  givenname: Svante
  orcidid: 0000-0001-5977-3049
  surname: Vikingsson
  fullname: Vikingsson, Svante
– sequence: 4
  givenname: Edward J
  surname: Cone
  fullname: Cone, Edward J
– sequence: 5
  givenname: Ruth E
  surname: Winecker
  fullname: Winecker, Ruth E
– sequence: 6
  givenname: Eugene D
  surname: Hayes
  fullname: Hayes, Eugene D
– sequence: 7
  givenname: Ronald R
  surname: Flegel
  fullname: Flegel, Ronald R
BookMark eNotkDtOAzEYhC0EEkmg4gIukdASv_ZVwvKUItFAvXK8_wYnxg62NygdFeIAHICz5Cg5CQuhml-j0fyab4j2rbOA0Akl55SUfDyXcTxdyIYIvocGtBRpwgTh-2hAqMgSkWfkEA1DmBNCsyLjAxQrZ1fgg3YWu3bz_SYj-CQ4000N4OryCkeHt58fZfJ4V2FtN99hbeMzRK3wTIboe21Np5vt-9eFxZ01egFmjZXsAvw1Ll3QUa8AN76b4QghhiN00EoT4PhfR-jp5vqxuksmD7f31cUkUZTnPBFFmaWkv6YFACkphbLpLSUYSxuVN5SVsmhIJlmaZ436XSRUW0LOhOR5JvkIne56l969dv3n-kUHBcZIC64LNSt4wdKUMNJHz3ZR5V0IHtp66fWL9OuakvqXbd2zrf_Z8h8-EnPb
Cites_doi 10.1016/j.forsciint.2020.110561
10.1001/jamanetworkopen.2022.23019
10.1001/jamapsychiatry.2020.3567
10.1093/jat/bkr017
10.1089/can.2017.0009
10.3390/ph13090219
10.1007/s00414-022-02896-w
10.1159/000509550
10.1089/can.2015.0004
10.1089/can.2019.0024
10.1093/jat/bkab059
10.1016/j.yebeh.2021.108514
10.1016/j.forsciint.2020.110173
10.12688/f1000research.19931.1
ContentType Journal Article
DBID AAYXX
CITATION
7X8
DOI 10.1093/jat/bkad043
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 1945-2403
EndPage 635
ExternalDocumentID 10_1093_jat_bkad043
GroupedDBID ---
.2P
.I3
.ZR
0R~
29J
4.4
48X
5GY
5VS
5WD
A8Z
AABZA
AACZT
AAIMJ
AAJKP
AAKDD
AAMDB
AAMVS
AAOGV
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAVAP
AAVLN
AAYXX
ABEUO
ABIXL
ABJNI
ABKDP
ABMNT
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACIPV
ACUFI
ACUTJ
ACUTO
ADBBV
ADEYI
ADFTL
ADGKP
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZTZ
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AELWJ
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFGWE
AFIYH
AFOFC
AFXEN
AGINJ
AGQXC
AGSYK
AHXPO
AIAGR
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
ARIXL
ATGXG
AXUDD
AYOIW
BAYMD
BCRHZ
BEYMZ
BHONS
BQDIO
BSWAC
BTRTY
BVRKM
C45
CDBKE
CITATION
DAKXR
DILTD
DU5
D~K
EBD
EBS
EE~
EMOBN
ESTFP
F5P
F9B
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
H5~
HAR
HW0
HZ~
J21
KOP
KQ8
KSI
KSN
M49
NGC
NLBLG
NOMLY
NOYVH
NU-
O9-
OAWHX
OBOKY
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
Q1.
Q5Y
RHF
ROX
RUSNO
RW1
RXO
SV3
TEORI
TJX
TLC
TN5
YAE
YAYTL
YKOAZ
YXANX
7X8
ABSAR
ID FETCH-LOGICAL-c1373-489650373b8ee0911e9d896c4225dc7d129a8d06a2576dc16864cf9e724a376a3
ISSN 0146-4760
IngestDate Thu Jul 25 09:25:16 EDT 2024
Thu Sep 26 19:44:52 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1373-489650373b8ee0911e9d896c4225dc7d129a8d06a2576dc16864cf9e724a376a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-5977-3049
0000-0001-9397-8582
OpenAccessLink https://academic.oup.com/jat/advance-article-pdf/doi/10.1093/jat/bkad043/50878693/bkad043.pdf
PQID 2838255020
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_2838255020
crossref_primary_10_1093_jat_bkad043
PublicationCentury 2000
PublicationDate 2023-09-15
20230915
PublicationDateYYYYMMDD 2023-09-15
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-15
  day: 15
PublicationDecade 2020
PublicationTitle Journal of analytical toxicology
PublicationYear 2023
References Gerace (2023091515445577900_R4) 2021; 318
Miller (2023091515445577900_R6) 2022; 127
Greenwich Biosciences, Inc (2023091515445577900_R16) 2018
Kiselak (2023091515445577900_R17) 2020; 308
Spindle (2023091515445577900_R5) 2022; 5
Brenan Megan (2023091515445577900_R2)
115th Congress (2023091515445577900_R1)
Crippa (2023091515445577900_R11) 2020; 5
Dahlgren (2023091515445577900_R3) 2021; 78
Lachenmeier (2023091515445577900_R10) 2019; 8
Millar (2023091515445577900_R13) 2020; 13
Nahler (2023091515445577900_R8) 2017; 2
Sholler (2023091515445577900_R12) 2022; 46
Andrews (2023091515445577900_R7) 2012; 36
Merrick (2023091515445577900_R9) 2016; 1
Franz (2023091515445577900_R14) 2023; 137
ElSohly (2023091515445577900_R15) 2020; 3
References_xml – volume: 318
  year: 2021
  ident: 2023091515445577900_R4
  article-title: Determination of cannabinoids in urine, oral fluid and hair samples after repeated intake of CBD-rich cannabis by smoking
  publication-title: Forensic Science International
  doi: 10.1016/j.forsciint.2020.110561
  contributor:
    fullname: Gerace
– volume: 5
  year: 2022
  ident: 2023091515445577900_R5
  article-title: Cannabinoid content and label accuracy of hemp-derived topical products available online and at national retail stores
  publication-title: JAMA Network Open
  doi: 10.1001/jamanetworkopen.2022.23019
  contributor:
    fullname: Spindle
– volume: 78
  start-page: 335
  year: 2021
  ident: 2023091515445577900_R3
  article-title: Urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2020.3567
  contributor:
    fullname: Dahlgren
– volume: 36
  start-page: 61
  year: 2012
  ident: 2023091515445577900_R7
  article-title: Production of identical retention times and mass spectra for {delta}9-tetrahydrocannabinol and cannabidiol following derivatization with trifluoracetic anhydride with 1,1,1,3,3,3-hexafluoroisopropanol*
  publication-title: Journal of Analytical Toxicology
  doi: 10.1093/jat/bkr017
  contributor:
    fullname: Andrews
– volume: 2
  start-page: 81
  year: 2017
  ident: 2023091515445577900_R8
  article-title: A conversion of oral cannabidiol to delta9-tetrahydrocannabinol seems not to occur in humans
  publication-title: Cannabis Cannabinoid Res
  doi: 10.1089/can.2017.0009
  contributor:
    fullname: Nahler
– volume: 13
  year: 2020
  ident: 2023091515445577900_R13
  article-title: Towards better delivery of cannabidiol (CBD)
  publication-title: Pharmaceuticals (Basel)
  doi: 10.3390/ph13090219
  contributor:
    fullname: Millar
– volume: 137
  start-page: 79
  year: 2023
  ident: 2023091515445577900_R14
  article-title: Will tetrahydrocannabinol be formed from cannabidiol in gastric fluid? An in vivo experiment
  publication-title: International Journal of Legal Medicine
  doi: 10.1007/s00414-022-02896-w
  contributor:
    fullname: Franz
– volume: 3
  start-page: 1
  year: 2020
  ident: 2023091515445577900_R15
  article-title: Analysis of cannabidiol, delta(9)-tetrahydrocannabinol, and their acids in CBD oil/hemp oil products
  publication-title: Med Cannabis Cannabinoids
  doi: 10.1159/000509550
  contributor:
    fullname: ElSohly
– ident: 2023091515445577900_R1
  article-title: Public Law 115-334: Agriculture Improvement Act of 2018
  contributor:
    fullname: 115th Congress
– volume: 1
  start-page: 102
  year: 2016
  ident: 2023091515445577900_R9
  article-title: Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid
  publication-title: Cannabis Cannabinoid Res
  doi: 10.1089/can.2015.0004
  contributor:
    fullname: Merrick
– volume: 5
  start-page: 89
  year: 2020
  ident: 2023091515445577900_R11
  article-title: Oral cannabidiol does not convert to delta(8)-THC or delta(9)-THC in humans: a pharmacokinetic study in healthy subjects
  publication-title: Cannabis Cannabinoid Res
  doi: 10.1089/can.2019.0024
  contributor:
    fullname: Crippa
– volume: 46
  start-page: 494
  year: 2022
  ident: 2023091515445577900_R12
  article-title: Urinarypharmacokinetic profile of cannabidiol (CBD), delta9-tetrahydrocannabinol (THC) and their metabolites following oral and vaporized CBD and vaporized CBD-dominant cannabis administration
  publication-title: Journal of Analytical Toxicology
  doi: 10.1093/jat/bkab059
  contributor:
    fullname: Sholler
– ident: 2023091515445577900_R2
  article-title: 14% of Americans Say They Use CBD Products
  contributor:
    fullname: Brenan Megan
– volume: 127
  year: 2022
  ident: 2023091515445577900_R6
  article-title: Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: implications for patients and practitioners
  publication-title: Epilepsy & Behavior : E&B
  doi: 10.1016/j.yebeh.2021.108514
  contributor:
    fullname: Miller
– volume: 308
  year: 2020
  ident: 2023091515445577900_R17
  article-title: Synthetic route sourcing of illicit at home cannabidiol (CBD) isomerization to psychoactive cannabinoids using ion mobility-coupled-LC-MS/MS
  publication-title: Forensic Science International
  doi: 10.1016/j.forsciint.2020.110173
  contributor:
    fullname: Kiselak
– volume: 8
  year: 2019
  ident: 2023091515445577900_R10
  article-title: Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
  publication-title: F1000Res
  doi: 10.12688/f1000research.19931.1
  contributor:
    fullname: Lachenmeier
– year: 2018
  ident: 2023091515445577900_R16
  article-title: EPIDIOLEX® (cannabidiol) oral solution, Instructions for Use (rev. 6/2018)
  contributor:
    fullname: Greenwich Biosciences, Inc
SSID ssj0016863
Score 2.3957744
Snippet Abstract Cannabidiol (CBD) has been shown to convert to ∆9-tetrahydrocannabinol (∆9-THC) in acidic environments, raising a concern of conversion when exposed...
SourceID proquest
crossref
SourceType Aggregation Database
StartPage 632
Title Conversion of water-soluble CBD to ∆9-THC in synthetic gastric fluid—An unlikely cause of positive drug tests
URI https://search.proquest.com/docview/2838255020
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKckFCiKdYXjLScoqym83DiY9LaVXBsgiRot4i13ZW2a0S1E32wQ9A_E5-CTOx0zZSDwuXKLUiV5n5Mv5mPDMmZG8eqACWDeHm0vPcUArmJlwql-daKR9cOZZjvfPnEzaZhh9n0WwwuN7IWmrq-b78ubWu5H-0CmOgV6yS_QfNriaFAbgH_cIVNAzXW-l4iCnjbbwLOd8V0Mali_-I1VDD9x-QV7bJDMm7hHE3nQwxunFxUwLpwz6tpwIP7ZBOvmgK5R6VTlMuinO9uHGkaEyM3-R0XWpHLZtTB2ipafy0hc4K7G5iAuN1dV3IXrh-Ikxl0AhQtlhn22Lrb1P6IK6Wm_D7XrQRfFsN9u0S1b_aLalMENYcN223tWzcwg8wycJUbu5rY2t5GOHmTrBpjE37TQu6eMOyMhsG1fZXtNX-m95YZwLeaTw_F8ozPaD6fbZPvmTj6fFxlo5m6R1y1495hG77p6_r_SeWsMBWc8KUBzDhgZ2uz1_6y3fLSdKH5IGVPj0yyHhEBrp8TO6bSCw1BWZPSLVGCa1y2kMJBZTQuqJ_fv9q8UGLkq7wQS0-aIcP2uGDtvjA2Tp8UMQHbfHxlEzHo3Q4ce0xG648DOLADRMONB3u5onWQB8PNVcwJEMw9UrGChihSJTHBPqmSqJsQplzHcMnDsuTCJ6RnRJU_5xQBuuBn0cs4aEXSga2XvLc82UuIs5zxXfJXie87IfpppKZLIggAxlnVsa75G0n2AysHW5hiVJXzUUGZDgBJxh8nBe3eOYlubdG3iuyUy8b_Ro4ZD1_06r7L7BceiA
link.rule.ids 315,786,790,27957,27958
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Conversion+of+water-soluble+CBD+to+%E2%88%869-THC+in+synthetic+gastric+fluid-An+unlikely+cause+of+positive+drug+tests&rft.jtitle=Journal+of+analytical+toxicology&rft.au=Hart%2C+E+Dale&rft.au=Mullen%2C+Lawrance&rft.au=Vikingsson%2C+Svante&rft.au=Cone%2C+Edward+J&rft.date=2023-09-15&rft.eissn=1945-2403&rft.volume=47&rft.issue=7&rft.spage=632&rft.epage=635&rft_id=info:doi/10.1093%2Fjat%2Fbkad043&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-4760&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-4760&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-4760&client=summon